News - Zetia, Januvia

Filter

Current filters:

ZetiaJanuvia

Popular Filters

1 to 25 of 26 results

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

24-01-2014

USA-based Amgen yesterday revealed positive results from the Phase III GAUSS-2 (Goal Achievement After…

AmgenBiotechnologyCardio-vascularevolocumabResearchZetia

New ACC and AHA guidelines could increase sales of statins

New ACC and AHA guidelines could increase sales of statins

13-11-2013

New clinical guidelines have been published for the treatment of cholesterol in people at high risk of…

AbbVieAstraZenecaCardio-vascularCrestorHealthcareLipitorMerck & CoNorth AmericaPfizerPharmaceuticalTricorUSAZetia

Avanir to promote Merck's diabetes drug Januvia

13-08-2013

US drugmaker Avanir Pharmaceuticals (Nasdaq: AVNR) has entered into an exclusive agreement with US drug…

Avanir PharmaceuticalsDiabetesJanuviaMarkets & MarketingMerck & CoNorth AmericaPharmaceutical

Merck & Co records loss in 2nd quarter as Singulair drops 80%

30-07-2013

US pharma giant Merck & Co (NYSE: MRK) has released second quarter results showing that worldwide sales…

FinancialGardasilIsentressJanumetJanuviaMerck & CoNorth AmericaPharmaceuticalRemicadeSimponi ARIASingulairVytorinZetia

American Diabetes Association calls for independent review of incretin-based therapy

12-06-2013

The American Diabetes Association is asking all pharmaceutical companies involved in the development…

DiabetesJanuviaMerck & CoPharmaceuticalRegulationResearch

Higher risk of pancreatitis for those taking new class of diabetes drugs, Johns Hopkins study finds

26-02-2013

People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those…

Bristol-Myers SquibbByettaDiabetesJanuviaMerck & CoPharmaceuticalResearch

South Korea's type 2 diabetes drug market to grow to over $550 million in 2016

23-10-2012

The type 2 diabetes therapeutic market in South Korea will grow 11% annually from $330 million in 2011…

AmylinAsia-PacificBydureonDiabetesJanumetJanuviaMarkets & MarketingMerck & CoNovo NordiskPharmaceuticalVictoza

GlaxoSmithKline readies for filing of diabetes drug albiglutide on positive final data

12-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) says that positive data from the Phase III Harmony 8 study…

albiglutideDiabetesGlaxoSmithKlineJanuviaMerck & CoPharmaceuticalRegulationResearch

Merck & Co 1st-qtr earnings just beat expectations; wins Mylan patent dispute

30-04-2012

US drug giant Merck & Co sales that global sales in the first-quarter of 2012 increased 1% to $11.7 billion,…

FinancialLegalMerck & CoMylan LaboratoriesNorth AmericaPatentsPharmaceuticalVytorinZetia

Victoza US label update includes superior efficacy over Januvia, says Novo Nordisk

10-04-2012

The US Food and Drug Administration has approved an update to the product label for Victoza (liraglutide…

DiabetesJanuviaLevemirMerck & CoNorth AmericaNovo NordiskPharmaceuticalRegulationResearchVictoza

Merck warned for not carrying out post-approval sitagliptin study

28-02-2012

The US Food and Drug Administration (FDA) has sent a warning letter to Merck & Co for failing to carry…

DiabetesJanumetJanuviaMerck & CoPharmaceuticalRegulationsitagliptinSitagliptin Metformin HCL

US FDA mixed views on Vytorin and Zetia

26-01-2012

US drug giant Merck & Co (NYSE: MRK) yesterday received Food and Drug Administration approval to update…

Cardio-vascularMerck & CoNephrology and HepatologyNorth AmericaPharmaceuticalRegulationVytorinZetia

Diabetes Rxing in China and S Korea

07-12-2011

Dipeptidyl peptidase IV (DPP-IV) inhibitors are prescribed more commonly for the treatment of type 2…

Asia-PacificDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisPharmaceuticalPricing

FDA clears Merck & Co’s combo diabetes/cholesterol therapy Juvisync

10-10-2011

The US Food and Drug Administration on Friday approved the marketing of the first combination drug to…

Cardio-vascularDiabetesJanuviaJuvisyncMerck & CoNorth AmericaPharmaceuticalRegulationZocor

1 to 25 of 26 results

Back to top